Compare Gilead Sciences, Inc. (GILD) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Peloton Interactive Inc — how do they compare? Gilead Sciences, Inc. trades at $135.59 (market cap $163.51B), while Peloton Interactive Inc trades at $6.32 (market cap $2.74B). The key difference: Gilead Sciences, Inc. is far larger — about 59.7× Peloton Interactive Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| GILD | PTON | |
|---|---|---|
Market Cap | $163.51B | $2.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $9.00 |
52-Week Low | $108.22 | $3.71 |
Enterprise Value | $178.05B | $3.34B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Peloton (PTON) trades at $6.39, up 3.73% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows improving fundamentals, with operating cash flow turning positive at $333 million in 2025 and net losses narrowing to -$119 million. Recent news highlights stabilization efforts, including a new CFO appointment and inclusion in the S&P SmallCap 600 index, though revenue declines persist.
The outlook remains cautious; while cost cuts drive profitability improvements, sustained revenue growth is elusive. Analyst consensus is a Buy with a $7.50 target, but high debt and negative equity pose significant risks. The stock's near-term performance hinges on execution of the turnaround strategy amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
